CA2078899A1 - Bioadhesive pharmaceutical carrier - Google Patents
Bioadhesive pharmaceutical carrierInfo
- Publication number
- CA2078899A1 CA2078899A1 CA002078899A CA2078899A CA2078899A1 CA 2078899 A1 CA2078899 A1 CA 2078899A1 CA 002078899 A CA002078899 A CA 002078899A CA 2078899 A CA2078899 A CA 2078899A CA 2078899 A1 CA2078899 A1 CA 2078899A1
- Authority
- CA
- Canada
- Prior art keywords
- bioadhesive
- dosage form
- pharmaceutical
- xanthan gum
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/14—Topical contraceptives and spermacides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/15—Suppositories
Abstract
BIOADHESIVE PHARMACEUTICAL CARRIER
Abstract of the Invention Bioadhesive pharmaceutical carrier consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate. The invention also provides for a method of control releasing a pharmaceutical active comprising incorporating an active into the bioadhesive pharmaceutical carrier. The invention is particularly adaptable for oral use and teething gels.
Abstract of the Invention Bioadhesive pharmaceutical carrier consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate. The invention also provides for a method of control releasing a pharmaceutical active comprising incorporating an active into the bioadhesive pharmaceutical carrier. The invention is particularly adaptable for oral use and teething gels.
Description
2~78~
BIOADHESIVE PHARMACEUTICAL CARRIER
Field of the Invention This invention relates to bioadhesive pharmaceutical carriers. More specifically, the pharmaceutical carrier is a liquid gel matrix comprising a particular polymer blend.
Back~round of the Invention Topical chemotherapeutic treatment of mucous membranes or other moist areas of the human body is problematic because of the inherent challenge of maintaining the localization of the pharmaceutical at the point of contact. In the mouth area, for example, in the cheeks, gums, tongue, or pallet area, as well as the lips, it is difficult to maintain a presence of a topically applied pharmaceutical because of its tendency to wash away with the patient's saliva and movements of the mouth which are normally present. While various bioadhesive formulations have been proposed for application to such moist areas, they have not been completely successful and there exists the need for additional bioadhesive pharmaceutical carrier materials for application to mucous membrane and other moist body areas.
For example, Gallopo et al. in U.S. Patent No. 4,915,948 have developed a tablets for bioadhesion to mucous membranes. The tablets comprise effective amounts of a water soluble biopolymer selected from the group consisting of a xanthan gum, a pectin, and mixtures thereof and a solid polyol. The polyol may be a sugar alcohol such as sorbitol or xylitolO Various pharmaceutical additives can be provided in such a tablet ., ~ . , .
:. , . , ' ~ , .
~7~
to provide for a controlled release of such pharmaceutical actives. It is the object of the present invention to provide a more convenient bioadhesive pharmaceutical carrier that can be applied to mucous membrane and other moist body areas which is in a gel form that not only provides good bioadhesion but also control release of pharmaceuticals therefrom.
Summary of the Invention It is therefore an object of the present invention to provide a bioadhesive pharmaceutical carrier in liquid gel matrix form for application to mucous membranes and other moist body parts for the controlled release of pharmaceutical actives thereto.
As embodied and fully described herein, the present invention provides a bioadhesive pharmaceutical carrier consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate. In other embodiments the invention provides bioadhesive pharmaceutical dosage form in solid or semi-solid form consisting essentially of an effective amount of a pharmaceutical active composition dispensed in a polymer blend of sodium carboxymethyl cellulose and xanthan gum. Preferably, the bioadhesive dosage form is in semi-solid form and comprises from about 0.25% to 50%
sodium carboxymethyl cellulose and xanthan gum or sodium alginate and from about 0.25 to 50% of these components by weight of the total weight of the pharmaceutical product.
In preferred embodiments, the dosage form additionally comprises a water soluble viscous vehicle material. In other embodiments, the bioadhesive dosage form ;~
:
2 ~ 7~
additionally comprises a viscous vehicle material which has low water solubility or is water insoluble.
In a preferred embodiment, the invention comprises a teething gel product comprising a bioadhesive pharmaceutical carrier and an anesthetic. In other embodiments, the invention comprises a method of control releasing a pharmaceutical active comprising incorporating the active in a bioadhesive pharmaceutical carrier comprising a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate.
Detailed Description of Preferred Embodiments of the Invention Reference will now be made in detail to preferred embodiments of the invention. Examples of which are illustrated in the following example section.
To achieve the objects of the invention a bioadhesive ? pharmaceutical carrier or dosage form is provided which consists essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate in which is dispersed a pharmaceutical active. The pharmaceutical carrier or dosage form of the invention can be in semi-solid (e.g. gel) or solid (e.g. powder) form.
In preferred embodiments the carrier or dosage form is a semi-solid comprising, in weight by weight of the total product, of from about 0.25 to 25%, more preferably about 10 to 20% and most preferably about 15 to 20% of each of sodium carboxymethyl cellulose and xanthan gum or about 0.25 to 25%, more preferably 10 to 20% and most preferably 10 to 15% sodium alginate as a substitute for the xanthan gum. In other preferred embodiments of a solid form the carrier comprises in weight by weight of the total product - - - ; . - ,:
.
, :
~7~3~
o~ from about 0.25 to 50%, more preferably 15 to 25% and most preferably 15 to 20% of each of sodium carboxymethyl cellulose and xanthan gum or about 0.25 to 50~, more preferably about 15 to 25~ and most preferably 20 to 25%
or sodium alginate as a substitute for xanthan gum.
The bioadhesive pharmaceutical carrier is a single matrix in the form of a liquid gel. This form is very convenient since it can be molded to the area of application and also can be appropriately metered in amounts and dosages as needed. This dosage form is therefore conveniently adhered to the mucous membranes in the mouth including, for example, cheeks, gums, tongue, pallet, etc., as well as to the lips. This dosage form is also applicable to the rectal, anal, vaginal, or nasal tissues, as well as the ear and eye areas of the body. Further, the dosage form can be applied in a powder or sprinkle form which gels upon contact with body fluids and bioadheres to the immediate body area.
The gel dosage form of the present invention has a smooth feel and is non-gritty for comfortable application to the intended areas of the body. Further, the gel dosage form requires no alcohol be present which is particularly suitable for use in treating children or sensitive areas such as inflamed, raw or sore spots (e.g., canker sores, fever blisters, hemorrhoids, etc.).
In addition to the polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate, it may be desirable to add a diluent or vehicle material which can be water soluble or have low water solubility be water insoluble. Preferred water soluble vehicle materials include glycerin, propylene glycol, dioxolanes, glycerol, :
,:. : ;
::
., ~ ' . .
2~7~3~
glycofurol, dlmethylacetamide, ethyl lactate, alcohols, glycols and sorbitols. Preferably the water soluble vehicle material is a polyethylene glycol wit a molecular weight of between 300 and 20,000 or mixtures thereof.
Other preferred vehicle materials include viscous vehicle materials which have low water solubility or are water insoluble and are selected from the group consisting of USP and NF oils (e.g. mineral oil, castor oil, corn oil, mineral oil, peanut oil, sesame oil and waxes), lanolin, hydrophilic petrolatum, anhydrous lanolin, lecithin, ethyl oleate, isopropyl myristate, benzyl benzoate, petrolatum, cocoa butter. Generally, addition of water soluble vehicle materials will quicken release of the active material and water insoluble vehicle materials will retard release of the active material from the bioadhesive dosage form.
Various pharmaceutical actives can be included in the bioadhesive dosage form. Examples of such pharmaceutical actives include but are not limited to anesthetics including benzocaine, pramoxine, dibucaine, diclonine, lidocaine, mepiracaine, prilocaine, and tetracaine;
demulcents (including benzoin, acacia, tragacanth, polyvinyl alcohol and glycerin; analgesics including opiate analgesics (e.g. codeine or hydrocodone), non-opiate analgesics, ~e.g. meperidine or methadone), non-narcotic analqesics including acetaminophen and NSAIDS
(e.g. s-ibuprofen, ketoprofen, fenoprofen, indomethacin, meclofenamate, mefenamic acid, naproxen,~phenylbutazone, piroxicam, tolmetin, sulindac, and dimethyl sulfoxide), astringents including calamine, zinc oxide, tannic acid, hamamelis water, zinc sulfate; wound cleansers (e.g.
benzalkonium chloride, carbamide perioxide, tannic acid, salicylic acid, triclosan, benzoyl peroxide, and boric .
acid); natural or synthetic steroids including triamcinolone acetonide, prednisone, beclomethasone dipropionate; asthmatic drugs including terbutaline sulfate, albuterol, leukotriene receptor antagonists;
electrolytes, me~als and minerals; antianxiety and antidepressant agents; antimicrobial and antiviral agents (e.g. acyclovir, neomycin, bacitracin, polymyxin B, vidarabine, trifluridine, zidovucine, methenamine, nonoxynol sulfonamides and other antibiotics); wound healing agents (e.g. fish oils, shark liver oil, castor oil, sucralfate and liver yeast cell derivatives);
antihistamines (e.g. diphenhydramine, promethazine, cromolyn, cyproheptadine, and azatadine); immune suppression agents; cholesterol lowering agents; cardiac and high blood pressure agents; menthol; camphor;
ibuprofen and menthol; benzocaine and triamcinolone acetonide; and mixtures thereof.
Other pharmaceutically acceptable excipients may be added to the bioadhesive gel dosage form such as, for example, acidifying agents; antimicrobial preservatives;
antioxidants; buffering agents; colorings; flavors;
perfumes; sweeteners; and mixtures thereof.
The bioadhesive dosage form of the invention can take on various forms including, but not limited to, powders, gels, creams, ointments, suppositories, films, tablets, ~apsules, caplets, implants, emulsions, aerosols and sprays. Examples of applications include nasal sprays or gels, gel contraceptives and anti-cancer oncological treatments for direct application to affected body areas ~e.g., cervix). The dosage form is particuIarly suited for problematical drugs since smaller dosage amounts can 2~ 7 be applied and concentrated at the site of action and released in a metered and controlled manner.
A more preferred embodiment of the invention is a teething gel product or product for treating canker sores (i.e., fever blisters or cold sores) which comprises as a dosage form the bioadhesive carrier of the invention and an anesthetic. Such a teething gel product would also preferably contain flavoring ingredients. The polymeric ingredients of the present invention have an essentially neutral taste and therefore can be advantageously flavored to provide good tasting formulations for oral use.
Examples of teething gel products are included in the Examples section.
The present invention also comprises a method of control releasing pharmaceutical actives comprising incorporating such actives in a bioadhesive pharmaceutical carrier comprising the polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate as previously discussed. Additional ingredients such as diluents or vehicle materials are also incorporated therein as also previously discussed. The method of control releasing pharmaceutical actives in accordance with the invention comprises the steps of incorporating a pharmaceutical active into a bioadhesive dosage form matrix consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum; and administering the dosage form to a patient. In preferred embodiments, the release of the drug material is slowed by adding proportionally more xanthan gum in the polymer blend.
MCP~48 2~7~
In preferred methods of the invention, the dosage form is administered orally, nasally, rectally, vaginally, ophthalmically, optically or topically. In accordance with the method of the invention, the dosage form is preferably administered directly to the site of action.
More preferably, the dosage form is administered orally and most preferably to the lips, mouth or gum area.
In accordance with the invention, the pharmaceutical additive can be released in a effective amount over a period of time which will provide effective and efficient pharmaceutical action and reduce the amount of toxicity of the pharmaceutical active dose utilize. Such metered action is particularly useful in administering pharmaceutical compositions which may have acute toxicity at higher dosing levels. The fact that the present invention is intended for topical administration directly to the site of action would also require less amounts of the pharmaceutical additive to be used than would a systemic administration of a pharmaceutical.
In accordance with the methods of the invention, the dosage form may be a teething gel which i5 directly administered to the gums of a teething child. The anesthetic included in such a teething gel may be selected from the group consisting of benzocaine, pramoxine, dibucaine, diclonine, lidocaine, mepivacaine, prilocaine, procaine, tetracaine, and dimethisoquin their pharmaceutically acceptable salts and combinations thereof.
In use, the bioadhesive gel of the present invention provides a temporary adhesive of the gel dosage form to the intended site of action, e.g., mucous membrane. The :
. ' .
2~7~9~
body moisture present at the site of action initially provides adhesive properties to the bioadhesive gel matrix, but upon saturation the gel adhesive bond diminishes and brea]cs down. After time the polymer matrix diffuses away and the mucal surface returns to normal.
~mL~
The invention will now be illustrated by examples. The examples are not intended to be limiting of the scope of the present invention but read in conjunction with the detailed and general description above, provide furth2r understanding of the present invention and an outline of a process for preparing the compositions of the invention and methods of practicing the invention. ~ -Example I
Inqredients Percentage Na CMC 10 Xanthan Gum 10 Benzocaine 7.5 Polyethylene Glycol (PEG 400) 58 Polyethylene Glycol (PEG 3350) 14.5 Prepared at 85C.
General_~rocedure:
25 The PEGs are liquified by stirring and heating. The polymers, actives and inactives are added while either stirring above the melting point of the polymer or at cooler or room temperatures, depending upon the stability, solubility and glass transition temperature of the ingredients used.
The formulation of Example I is prepared by adding with stirring Na CMC and xanthan gum to a clear solution (65C) of PEG 600 and PEG 3350. The temperature was slowly 2 ~
increased with stirring to 85C. This temperature was maintained for one hour to swell and wet the polymer surfaces. The heat was removed and the mixture was allowed to cool. At 45C and with constant stirring, the benzocaine was added. The product was allowed to cool.
When congealing or gelling occurred, the stirring was stopped and the gel product packaged into tubes and ointment jars.
In other formulations, the flavors, colors, sweeteners, preservatives and glycerine were added together and introduced into the cooling PEG-polymer mixture at 50C.
Examples II-XI
The following examples are prepared in accordance with the procedures of Example I utilizing the following formulations with percentage of ingredients indicated for each example:
II III IV V VI
Inaredi~nts Glycerine 10 10 10 10 10 Na CMC 5 5 5 5 20 :
Xanthan gum 5 5 15 15 5 Benzocaine 7.5 7.5 7.5 7.5 7.5 Flavoring 0.15 0.15 0.150.15 0.15 Na saccharin 0.5 0.5 0.5 0.5 0.5 Methyl paraben 0.1 0.1 0.1 0.1 0.1 PEG 60Q 57.4 57.4 49.449.4 45.4 PEG 3350 14.4 14.4 12.412.4 11.35 Temperature 65 85 65 85 65 (C) .
.
,, , :~ .
.
2 ~ P~
VII VIII IX X XI
In~redients Glycerine 10 10 10 10 10 Na CMC 20 20 20 20 15 Xanthan gum 5 15 15 20 20 Benzocaine 7.5 7.5 7.57.5 7.5 Flavoring 0.15 0.15 0.150.15 0.15 Na saccharin 0.5 0.5 0.5 0.5 0.5 Methyl paraben 0.1 0.1 0.1 0.1 0.1 PEG 600 45.4 37.4 37.433.4 31.4 PEG 3350 11.35 9.35 9.358,4 9.4 Temperature 85 65 85 65 85 (C) Examples XII-XIV
XII XIII XIV
Inqredients Glycerine 10 10 10 Na CMC 20 20 15 Xanthan gum 15 20 20 Benzocaine 7.5 7.5 7.5 Flavoring 0.15 0.15 0.15 Na saccharin 0.5 0.5 0.5 Methyl paraben 0.1 0.1 0.1 PEG 600 35.4 31.4 35.4 PEG 3350 8.9 7.9 8.9 Temperature 65 65 65 (C) Examples XV-XVII
xv xv r XVII
Inqredients Na CMC 10 10 10 Na Alginate 20 20 15 Benzocaine 7.5 7.5 7.5 PEG 400 58.0 50.0 58.0 PEG 3350 14.5 12.5 14.5 Temperature 85 ~5 85 (C) 2~7~
The benzocaine (active) release from the gel matrix examples of the invention is reported in Table 1 as a percentage of benzocaine released over 180 minutes for each of the formulations of Examples II-XIV. It is seen, for example, that Example II shows the quickest release, whereas Example XIII shows the slowest release, but virtually all of the benzocaine has been released by 180 minutes. It is apparent that such releases may be controlled for various applications by varying the particular formulations utilized.
Table 2 provides the results of a simulated adhesion of the gel of the invention to human gums by measuring the adhesion strength of the gels of the invPntion of Examples II-XII to glass. The gels of the invention are also favorably compared to control gels and a commercial product identified by its trademark ORABASE B. The results provided in Table 2 demonstrate the excellent wet adhesion strength of the gels of the invention even after soaking ln normal saline solution for three minutes.
': . , :
, - : (:' " ' -2 ~ ~ o 8 ~ 9 X t~ ~ CO O H ~` ~ H H t` ') O
d~ , .-1 ~ ~) Ul r` O H ~ 0 0 o m u~
H
C _~ H H ~ O O (~ O ~ 1~ ~1 O
H ,~ It) t` O ~ H ~ ul O
G ~
~ o H ~r ~D ~ ~ In O t~ D 1` 1" O
O tn ~ h H H ~ ~) ~) a~ O ~ ~0 H H ~ O O
~a ~Q ~
H ~ r` LO O ISl O H ~ H 1` 0 0 h ~ ~ ~ ~D co o X ~
u~ o ~1 m co o ~1 ~ t~ o E`i o ~ ~. ~ D 00 0 H H H7 10 1 0 S N
H ~ 1 0 H ~1 ~ 'r ~D Cl~ HX H ~~ D I O
al O
O ~ O a~ H r l 1` Ir) ~ O H c0 ~0 ~1 0 ~D ~D O
rl O-r~ ta H ~ r ~D ~ O ~ ~ H ~ ~r ~D CO O
O o a~ :
N O N 0 ~
: a~ Q) a~ ,l H O O ~ O X ct) ~ ~10 0 Ir) O
H ~ O H ~ ~ ~ 1 O
~ .
a a ~ X : ' ~ X
~_ ~oInoooo ~_InOIno~oo ~1 rl ~1 ~ ~D N 00 rlH H ~
~1 ~
~1 0 ~1 o CO
. . . .
"', '' ' ~ ' , : ' ' , : ~ `
f 2~7 Ul oooooooo ooooo U
o S ~ ~ El ~ Q
~ a) a o 1 1~; .
~ ~
o-,l ooooooOO OOOOO O--U~ ~ ~
. ~ :
o, .
u~ I ~r ~ co ,1 ~ ,1 ,~ ~ ,1 ~ ~ ,1 o~ ~ ~ >1 O ~ ., ~ D r- w ~ ~ o o ~ ~ l Si In U~ ~ ~ O O O O O O O O ~ O O O
$ h O
J~ ~
U~ t) Q~ g Ql o__ Cc~ r ~ o ~ D O ~
O ,~ OOOOOOO~OOt~OO S
~ ~ o a) o .C ~ N U~ N
t~ U~ ~ O C:
U~ a) r-l a) : ~ a) Q :S Q
o~ ~1 o\O
In 11 0 ~ Lr) ~ ~ ~ U
~ ~ E~
O tr~ 'H H ~ H H H X X H H ~1 ~i ~ O H H H~ H H H X H O U~
0 L O Z H ~ H X h ¢ X ~) Ul ~ ~ m X O ~ ~ ~
.C H 1~ C.~ O a) U~ X O
~1 ~ Q~l ~
E~ ~a o O
a~
P~
-, j . .. : ' ~ :: -, `., ;~:
2~7~
The scope of the present invention is not limited by the description, examples, and suggested uses herein, and modifications can be made without departing from the spirit of the invention. For example, the bioadhesive gel matrix of the invention can be used as a carrier for vitamin or mineral products or other nutrients for which a sustained release to a particular area or site is desirable.
Application of the compositions and methods of the present invention for medical and pharmaceutical uses can be accomplished by any clinical, medical, and pharmaceutical method and technique as would be presently or prospectively known to those skilled in the art. For example, the bioadhesive composition of the present invention may be employed in various other dosage forms including, without limitation, tablets, ointments, creams, suppositories, injection molded particles or tablets, films, emulsions, aerosols, spray congealed particles and implants. Thus, it is intended that the present invention cover the modifications and variations o~ this invention provided that they come within the scope of the appended claims and their equivalents.
: :~
BIOADHESIVE PHARMACEUTICAL CARRIER
Field of the Invention This invention relates to bioadhesive pharmaceutical carriers. More specifically, the pharmaceutical carrier is a liquid gel matrix comprising a particular polymer blend.
Back~round of the Invention Topical chemotherapeutic treatment of mucous membranes or other moist areas of the human body is problematic because of the inherent challenge of maintaining the localization of the pharmaceutical at the point of contact. In the mouth area, for example, in the cheeks, gums, tongue, or pallet area, as well as the lips, it is difficult to maintain a presence of a topically applied pharmaceutical because of its tendency to wash away with the patient's saliva and movements of the mouth which are normally present. While various bioadhesive formulations have been proposed for application to such moist areas, they have not been completely successful and there exists the need for additional bioadhesive pharmaceutical carrier materials for application to mucous membrane and other moist body areas.
For example, Gallopo et al. in U.S. Patent No. 4,915,948 have developed a tablets for bioadhesion to mucous membranes. The tablets comprise effective amounts of a water soluble biopolymer selected from the group consisting of a xanthan gum, a pectin, and mixtures thereof and a solid polyol. The polyol may be a sugar alcohol such as sorbitol or xylitolO Various pharmaceutical additives can be provided in such a tablet ., ~ . , .
:. , . , ' ~ , .
~7~
to provide for a controlled release of such pharmaceutical actives. It is the object of the present invention to provide a more convenient bioadhesive pharmaceutical carrier that can be applied to mucous membrane and other moist body areas which is in a gel form that not only provides good bioadhesion but also control release of pharmaceuticals therefrom.
Summary of the Invention It is therefore an object of the present invention to provide a bioadhesive pharmaceutical carrier in liquid gel matrix form for application to mucous membranes and other moist body parts for the controlled release of pharmaceutical actives thereto.
As embodied and fully described herein, the present invention provides a bioadhesive pharmaceutical carrier consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate. In other embodiments the invention provides bioadhesive pharmaceutical dosage form in solid or semi-solid form consisting essentially of an effective amount of a pharmaceutical active composition dispensed in a polymer blend of sodium carboxymethyl cellulose and xanthan gum. Preferably, the bioadhesive dosage form is in semi-solid form and comprises from about 0.25% to 50%
sodium carboxymethyl cellulose and xanthan gum or sodium alginate and from about 0.25 to 50% of these components by weight of the total weight of the pharmaceutical product.
In preferred embodiments, the dosage form additionally comprises a water soluble viscous vehicle material. In other embodiments, the bioadhesive dosage form ;~
:
2 ~ 7~
additionally comprises a viscous vehicle material which has low water solubility or is water insoluble.
In a preferred embodiment, the invention comprises a teething gel product comprising a bioadhesive pharmaceutical carrier and an anesthetic. In other embodiments, the invention comprises a method of control releasing a pharmaceutical active comprising incorporating the active in a bioadhesive pharmaceutical carrier comprising a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate.
Detailed Description of Preferred Embodiments of the Invention Reference will now be made in detail to preferred embodiments of the invention. Examples of which are illustrated in the following example section.
To achieve the objects of the invention a bioadhesive ? pharmaceutical carrier or dosage form is provided which consists essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate in which is dispersed a pharmaceutical active. The pharmaceutical carrier or dosage form of the invention can be in semi-solid (e.g. gel) or solid (e.g. powder) form.
In preferred embodiments the carrier or dosage form is a semi-solid comprising, in weight by weight of the total product, of from about 0.25 to 25%, more preferably about 10 to 20% and most preferably about 15 to 20% of each of sodium carboxymethyl cellulose and xanthan gum or about 0.25 to 25%, more preferably 10 to 20% and most preferably 10 to 15% sodium alginate as a substitute for the xanthan gum. In other preferred embodiments of a solid form the carrier comprises in weight by weight of the total product - - - ; . - ,:
.
, :
~7~3~
o~ from about 0.25 to 50%, more preferably 15 to 25% and most preferably 15 to 20% of each of sodium carboxymethyl cellulose and xanthan gum or about 0.25 to 50~, more preferably about 15 to 25~ and most preferably 20 to 25%
or sodium alginate as a substitute for xanthan gum.
The bioadhesive pharmaceutical carrier is a single matrix in the form of a liquid gel. This form is very convenient since it can be molded to the area of application and also can be appropriately metered in amounts and dosages as needed. This dosage form is therefore conveniently adhered to the mucous membranes in the mouth including, for example, cheeks, gums, tongue, pallet, etc., as well as to the lips. This dosage form is also applicable to the rectal, anal, vaginal, or nasal tissues, as well as the ear and eye areas of the body. Further, the dosage form can be applied in a powder or sprinkle form which gels upon contact with body fluids and bioadheres to the immediate body area.
The gel dosage form of the present invention has a smooth feel and is non-gritty for comfortable application to the intended areas of the body. Further, the gel dosage form requires no alcohol be present which is particularly suitable for use in treating children or sensitive areas such as inflamed, raw or sore spots (e.g., canker sores, fever blisters, hemorrhoids, etc.).
In addition to the polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate, it may be desirable to add a diluent or vehicle material which can be water soluble or have low water solubility be water insoluble. Preferred water soluble vehicle materials include glycerin, propylene glycol, dioxolanes, glycerol, :
,:. : ;
::
., ~ ' . .
2~7~3~
glycofurol, dlmethylacetamide, ethyl lactate, alcohols, glycols and sorbitols. Preferably the water soluble vehicle material is a polyethylene glycol wit a molecular weight of between 300 and 20,000 or mixtures thereof.
Other preferred vehicle materials include viscous vehicle materials which have low water solubility or are water insoluble and are selected from the group consisting of USP and NF oils (e.g. mineral oil, castor oil, corn oil, mineral oil, peanut oil, sesame oil and waxes), lanolin, hydrophilic petrolatum, anhydrous lanolin, lecithin, ethyl oleate, isopropyl myristate, benzyl benzoate, petrolatum, cocoa butter. Generally, addition of water soluble vehicle materials will quicken release of the active material and water insoluble vehicle materials will retard release of the active material from the bioadhesive dosage form.
Various pharmaceutical actives can be included in the bioadhesive dosage form. Examples of such pharmaceutical actives include but are not limited to anesthetics including benzocaine, pramoxine, dibucaine, diclonine, lidocaine, mepiracaine, prilocaine, and tetracaine;
demulcents (including benzoin, acacia, tragacanth, polyvinyl alcohol and glycerin; analgesics including opiate analgesics (e.g. codeine or hydrocodone), non-opiate analgesics, ~e.g. meperidine or methadone), non-narcotic analqesics including acetaminophen and NSAIDS
(e.g. s-ibuprofen, ketoprofen, fenoprofen, indomethacin, meclofenamate, mefenamic acid, naproxen,~phenylbutazone, piroxicam, tolmetin, sulindac, and dimethyl sulfoxide), astringents including calamine, zinc oxide, tannic acid, hamamelis water, zinc sulfate; wound cleansers (e.g.
benzalkonium chloride, carbamide perioxide, tannic acid, salicylic acid, triclosan, benzoyl peroxide, and boric .
acid); natural or synthetic steroids including triamcinolone acetonide, prednisone, beclomethasone dipropionate; asthmatic drugs including terbutaline sulfate, albuterol, leukotriene receptor antagonists;
electrolytes, me~als and minerals; antianxiety and antidepressant agents; antimicrobial and antiviral agents (e.g. acyclovir, neomycin, bacitracin, polymyxin B, vidarabine, trifluridine, zidovucine, methenamine, nonoxynol sulfonamides and other antibiotics); wound healing agents (e.g. fish oils, shark liver oil, castor oil, sucralfate and liver yeast cell derivatives);
antihistamines (e.g. diphenhydramine, promethazine, cromolyn, cyproheptadine, and azatadine); immune suppression agents; cholesterol lowering agents; cardiac and high blood pressure agents; menthol; camphor;
ibuprofen and menthol; benzocaine and triamcinolone acetonide; and mixtures thereof.
Other pharmaceutically acceptable excipients may be added to the bioadhesive gel dosage form such as, for example, acidifying agents; antimicrobial preservatives;
antioxidants; buffering agents; colorings; flavors;
perfumes; sweeteners; and mixtures thereof.
The bioadhesive dosage form of the invention can take on various forms including, but not limited to, powders, gels, creams, ointments, suppositories, films, tablets, ~apsules, caplets, implants, emulsions, aerosols and sprays. Examples of applications include nasal sprays or gels, gel contraceptives and anti-cancer oncological treatments for direct application to affected body areas ~e.g., cervix). The dosage form is particuIarly suited for problematical drugs since smaller dosage amounts can 2~ 7 be applied and concentrated at the site of action and released in a metered and controlled manner.
A more preferred embodiment of the invention is a teething gel product or product for treating canker sores (i.e., fever blisters or cold sores) which comprises as a dosage form the bioadhesive carrier of the invention and an anesthetic. Such a teething gel product would also preferably contain flavoring ingredients. The polymeric ingredients of the present invention have an essentially neutral taste and therefore can be advantageously flavored to provide good tasting formulations for oral use.
Examples of teething gel products are included in the Examples section.
The present invention also comprises a method of control releasing pharmaceutical actives comprising incorporating such actives in a bioadhesive pharmaceutical carrier comprising the polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate as previously discussed. Additional ingredients such as diluents or vehicle materials are also incorporated therein as also previously discussed. The method of control releasing pharmaceutical actives in accordance with the invention comprises the steps of incorporating a pharmaceutical active into a bioadhesive dosage form matrix consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum; and administering the dosage form to a patient. In preferred embodiments, the release of the drug material is slowed by adding proportionally more xanthan gum in the polymer blend.
MCP~48 2~7~
In preferred methods of the invention, the dosage form is administered orally, nasally, rectally, vaginally, ophthalmically, optically or topically. In accordance with the method of the invention, the dosage form is preferably administered directly to the site of action.
More preferably, the dosage form is administered orally and most preferably to the lips, mouth or gum area.
In accordance with the invention, the pharmaceutical additive can be released in a effective amount over a period of time which will provide effective and efficient pharmaceutical action and reduce the amount of toxicity of the pharmaceutical active dose utilize. Such metered action is particularly useful in administering pharmaceutical compositions which may have acute toxicity at higher dosing levels. The fact that the present invention is intended for topical administration directly to the site of action would also require less amounts of the pharmaceutical additive to be used than would a systemic administration of a pharmaceutical.
In accordance with the methods of the invention, the dosage form may be a teething gel which i5 directly administered to the gums of a teething child. The anesthetic included in such a teething gel may be selected from the group consisting of benzocaine, pramoxine, dibucaine, diclonine, lidocaine, mepivacaine, prilocaine, procaine, tetracaine, and dimethisoquin their pharmaceutically acceptable salts and combinations thereof.
In use, the bioadhesive gel of the present invention provides a temporary adhesive of the gel dosage form to the intended site of action, e.g., mucous membrane. The :
. ' .
2~7~9~
body moisture present at the site of action initially provides adhesive properties to the bioadhesive gel matrix, but upon saturation the gel adhesive bond diminishes and brea]cs down. After time the polymer matrix diffuses away and the mucal surface returns to normal.
~mL~
The invention will now be illustrated by examples. The examples are not intended to be limiting of the scope of the present invention but read in conjunction with the detailed and general description above, provide furth2r understanding of the present invention and an outline of a process for preparing the compositions of the invention and methods of practicing the invention. ~ -Example I
Inqredients Percentage Na CMC 10 Xanthan Gum 10 Benzocaine 7.5 Polyethylene Glycol (PEG 400) 58 Polyethylene Glycol (PEG 3350) 14.5 Prepared at 85C.
General_~rocedure:
25 The PEGs are liquified by stirring and heating. The polymers, actives and inactives are added while either stirring above the melting point of the polymer or at cooler or room temperatures, depending upon the stability, solubility and glass transition temperature of the ingredients used.
The formulation of Example I is prepared by adding with stirring Na CMC and xanthan gum to a clear solution (65C) of PEG 600 and PEG 3350. The temperature was slowly 2 ~
increased with stirring to 85C. This temperature was maintained for one hour to swell and wet the polymer surfaces. The heat was removed and the mixture was allowed to cool. At 45C and with constant stirring, the benzocaine was added. The product was allowed to cool.
When congealing or gelling occurred, the stirring was stopped and the gel product packaged into tubes and ointment jars.
In other formulations, the flavors, colors, sweeteners, preservatives and glycerine were added together and introduced into the cooling PEG-polymer mixture at 50C.
Examples II-XI
The following examples are prepared in accordance with the procedures of Example I utilizing the following formulations with percentage of ingredients indicated for each example:
II III IV V VI
Inaredi~nts Glycerine 10 10 10 10 10 Na CMC 5 5 5 5 20 :
Xanthan gum 5 5 15 15 5 Benzocaine 7.5 7.5 7.5 7.5 7.5 Flavoring 0.15 0.15 0.150.15 0.15 Na saccharin 0.5 0.5 0.5 0.5 0.5 Methyl paraben 0.1 0.1 0.1 0.1 0.1 PEG 60Q 57.4 57.4 49.449.4 45.4 PEG 3350 14.4 14.4 12.412.4 11.35 Temperature 65 85 65 85 65 (C) .
.
,, , :~ .
.
2 ~ P~
VII VIII IX X XI
In~redients Glycerine 10 10 10 10 10 Na CMC 20 20 20 20 15 Xanthan gum 5 15 15 20 20 Benzocaine 7.5 7.5 7.57.5 7.5 Flavoring 0.15 0.15 0.150.15 0.15 Na saccharin 0.5 0.5 0.5 0.5 0.5 Methyl paraben 0.1 0.1 0.1 0.1 0.1 PEG 600 45.4 37.4 37.433.4 31.4 PEG 3350 11.35 9.35 9.358,4 9.4 Temperature 85 65 85 65 85 (C) Examples XII-XIV
XII XIII XIV
Inqredients Glycerine 10 10 10 Na CMC 20 20 15 Xanthan gum 15 20 20 Benzocaine 7.5 7.5 7.5 Flavoring 0.15 0.15 0.15 Na saccharin 0.5 0.5 0.5 Methyl paraben 0.1 0.1 0.1 PEG 600 35.4 31.4 35.4 PEG 3350 8.9 7.9 8.9 Temperature 65 65 65 (C) Examples XV-XVII
xv xv r XVII
Inqredients Na CMC 10 10 10 Na Alginate 20 20 15 Benzocaine 7.5 7.5 7.5 PEG 400 58.0 50.0 58.0 PEG 3350 14.5 12.5 14.5 Temperature 85 ~5 85 (C) 2~7~
The benzocaine (active) release from the gel matrix examples of the invention is reported in Table 1 as a percentage of benzocaine released over 180 minutes for each of the formulations of Examples II-XIV. It is seen, for example, that Example II shows the quickest release, whereas Example XIII shows the slowest release, but virtually all of the benzocaine has been released by 180 minutes. It is apparent that such releases may be controlled for various applications by varying the particular formulations utilized.
Table 2 provides the results of a simulated adhesion of the gel of the invention to human gums by measuring the adhesion strength of the gels of the invPntion of Examples II-XII to glass. The gels of the invention are also favorably compared to control gels and a commercial product identified by its trademark ORABASE B. The results provided in Table 2 demonstrate the excellent wet adhesion strength of the gels of the invention even after soaking ln normal saline solution for three minutes.
': . , :
, - : (:' " ' -2 ~ ~ o 8 ~ 9 X t~ ~ CO O H ~` ~ H H t` ') O
d~ , .-1 ~ ~) Ul r` O H ~ 0 0 o m u~
H
C _~ H H ~ O O (~ O ~ 1~ ~1 O
H ,~ It) t` O ~ H ~ ul O
G ~
~ o H ~r ~D ~ ~ In O t~ D 1` 1" O
O tn ~ h H H ~ ~) ~) a~ O ~ ~0 H H ~ O O
~a ~Q ~
H ~ r` LO O ISl O H ~ H 1` 0 0 h ~ ~ ~ ~D co o X ~
u~ o ~1 m co o ~1 ~ t~ o E`i o ~ ~. ~ D 00 0 H H H7 10 1 0 S N
H ~ 1 0 H ~1 ~ 'r ~D Cl~ HX H ~~ D I O
al O
O ~ O a~ H r l 1` Ir) ~ O H c0 ~0 ~1 0 ~D ~D O
rl O-r~ ta H ~ r ~D ~ O ~ ~ H ~ ~r ~D CO O
O o a~ :
N O N 0 ~
: a~ Q) a~ ,l H O O ~ O X ct) ~ ~10 0 Ir) O
H ~ O H ~ ~ ~ 1 O
~ .
a a ~ X : ' ~ X
~_ ~oInoooo ~_InOIno~oo ~1 rl ~1 ~ ~D N 00 rlH H ~
~1 ~
~1 0 ~1 o CO
. . . .
"', '' ' ~ ' , : ' ' , : ~ `
f 2~7 Ul oooooooo ooooo U
o S ~ ~ El ~ Q
~ a) a o 1 1~; .
~ ~
o-,l ooooooOO OOOOO O--U~ ~ ~
. ~ :
o, .
u~ I ~r ~ co ,1 ~ ,1 ,~ ~ ,1 ~ ~ ,1 o~ ~ ~ >1 O ~ ., ~ D r- w ~ ~ o o ~ ~ l Si In U~ ~ ~ O O O O O O O O ~ O O O
$ h O
J~ ~
U~ t) Q~ g Ql o__ Cc~ r ~ o ~ D O ~
O ,~ OOOOOOO~OOt~OO S
~ ~ o a) o .C ~ N U~ N
t~ U~ ~ O C:
U~ a) r-l a) : ~ a) Q :S Q
o~ ~1 o\O
In 11 0 ~ Lr) ~ ~ ~ U
~ ~ E~
O tr~ 'H H ~ H H H X X H H ~1 ~i ~ O H H H~ H H H X H O U~
0 L O Z H ~ H X h ¢ X ~) Ul ~ ~ m X O ~ ~ ~
.C H 1~ C.~ O a) U~ X O
~1 ~ Q~l ~
E~ ~a o O
a~
P~
-, j . .. : ' ~ :: -, `., ;~:
2~7~
The scope of the present invention is not limited by the description, examples, and suggested uses herein, and modifications can be made without departing from the spirit of the invention. For example, the bioadhesive gel matrix of the invention can be used as a carrier for vitamin or mineral products or other nutrients for which a sustained release to a particular area or site is desirable.
Application of the compositions and methods of the present invention for medical and pharmaceutical uses can be accomplished by any clinical, medical, and pharmaceutical method and technique as would be presently or prospectively known to those skilled in the art. For example, the bioadhesive composition of the present invention may be employed in various other dosage forms including, without limitation, tablets, ointments, creams, suppositories, injection molded particles or tablets, films, emulsions, aerosols, spray congealed particles and implants. Thus, it is intended that the present invention cover the modifications and variations o~ this invention provided that they come within the scope of the appended claims and their equivalents.
: :~
Claims (30)
1. A bioadhesive pharmaceutical carrier composition consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate.
2. A bioadhesive pharmaceutical dosage form consisting essentially of an effective amount of a pharmaceutical active composition dispensed in a polymer blend of sodium carboxymethyl cellulose and xanthan gum.
3. The bioadhesive of Claim 2 wherein the dosage form additionally comprises a water soluble viscous vehicle material.
4. The bioadhesive carrier of Claim 1 comprising from about 0.25 to 25% of each of sodium carboxymethyl cellulose and sodium alginate by weight of the total weight of the pharmaceutical composition.
5. The bioadhesive of Claim 2 comprises from about 0.25 to 25% of each of sodium carboxymethyl cellulose and xanthan gum by weight of the total weight of the pharmaceutical composition.
6. The bioadhesive of Claim 3 wherein the vehicle material is selected from the group consisting of the water soluble vehicles: glycerin, propylene glycol, dioxolanes, glyerol, glycofurol, dimethylacetamide, ethyl lactate, alcohols, glycols and sorbitols.
7. The bioadhesive of Claim 3 wherein the vehicle material is a polyethylene glycol with a molecular weight of between 300 and 20,000 or mixtures thereof.
8. The bioadhesive of Claim 2 wherein the dosage form additionally comprises a viscous vehicle material which has low water solubility or is water insoluble and is selected from the group consisting of: USP and NF oils, lecithin, lanolin, ethyl oleate, isopropyl myristate, benzyl benzoate, petrolatum, and cocoa butter.
9. The bioadhesive of Claim 2 wherein the dosage form is selected from the group consisting of powders, gels, creams, ointments, suppositories, films, tablets, capsules, caplets, implants, emulsions, aerosols and sprays.
10. The bioadhesive of Claim 2 wherein the pharmaceutical active is selected from the group consisting of:
anesthetics; demulcents; analgesics; astringents including calamine, wound cleansers, natural or synthetic steroids;
asthmatic drugs; electrolytes, metals and minerals;
antianxiety and antidepressant agents; antimicrobial and antiviral agents; wound healing agents; antihistamines;
immune suppression agents; cholesterol lowering agents;
cardiac and high blood pressure agents; menthol; camphor;
pramoxin; ibuprofen and menthol; benzocaine and triamcinolone acetonide; and mixtures thereof.
anesthetics; demulcents; analgesics; astringents including calamine, wound cleansers, natural or synthetic steroids;
asthmatic drugs; electrolytes, metals and minerals;
antianxiety and antidepressant agents; antimicrobial and antiviral agents; wound healing agents; antihistamines;
immune suppression agents; cholesterol lowering agents;
cardiac and high blood pressure agents; menthol; camphor;
pramoxin; ibuprofen and menthol; benzocaine and triamcinolone acetonide; and mixtures thereof.
11. The bioadhesive of Claim 2 wherein the dosage form additionally comprises pharmaceutically acceptable excipients selected from the group consisting of:
acidifying agents; antimicrobial preservatives;
antioxidants; buffering agents; colorings; flavors, perfumes; sweeteners; and mixtures thereof.
acidifying agents; antimicrobial preservatives;
antioxidants; buffering agents; colorings; flavors, perfumes; sweeteners; and mixtures thereof.
12. A teething gel product comprising the bioadhesive of Claim 1 and an anesthetic.
13. A teething gel product comprising the bioadhesive of Claim 2 and an anesthetic.
14. A teething gel product comprising the bioadhesive of Claim 9 and an anesthetic.
15. The product of Claim 12 wherein the anesthetic is benzocaine.
16. The product of Claim 13 wherein the anesthetic is benzocaine.
17. A method of control releasing a pharmaceutical active comprising incorporating the active in a bioadhesive pharmaceutical carrier comprising a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate.
18. A method for control releasing of a pharmaceutical active comprising the steps of:
incorporating a pharmaceutical active into a bioadhesive dosage form matrix consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum;
and administering the dosage form to a patient.
incorporating a pharmaceutical active into a bioadhesive dosage form matrix consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum;
and administering the dosage form to a patient.
19. The method of Claim 18 wherein the dosage form is administered orally, nasally, rectally, vaginally, ophthalmically, otically or topically.
20. The method of Claim 18 wherein the dosage form is administered directly to the site of action.
21. The method of Claim 20 wherein the pharmaceutical active is released in an effective amount over a period of time to provide effective and efficient pharmaceutical action and reduce the amount of toxicity of the pharmaceutical active dose utilized.
22. The method of Claim 18 wherein the pharmaceutical active is an anesthetic.
23. The method of Claim 20 wherein the dosage form is a teething gel which is administered to the gums of a child.
24. The method of Claim 20 wherein the anesthetic is selected from the group consisting of benzocaine, pramoxine, dibucaine, diclonine, lidocaine, mepiracaine, prilocaine, tetracaine and procaine their pharmaceutically acceptable salts and combinations thereof.
25. The method of Claim 21 wherein the pharmaceutical active is acutely toxic at high dosages.
26. A teething gel product comprising in percentages by weight of the total product from about 5 to 10%
benzocaine; 5 to 15% glycerine; 5 to 20% NaCMC; 5 to 20%
xanthan gum; and 35 to 75% polyethylene glycol.
benzocaine; 5 to 15% glycerine; 5 to 20% NaCMC; 5 to 20%
xanthan gum; and 35 to 75% polyethylene glycol.
27. The teething gel of Claim 26 wherein the benzocaine is present in an amount of about 7.5% by weight.
28. The teething gel of Claim 27 wherein the glycerine is present in an amount of about 10% by weight.
29. The teething gel of Claim 26 wherein the product additionally comprises flavorings and preservatives.
30. The teething gel of Claim 26 wherein the polyethylene glycol is a mixture of about 30 to 60% polyethylene glycol with an average molecular weight of 600 and about 5 to 15%
polyethylene glycol with an average molecular weight of 3350.
polyethylene glycol with an average molecular weight of 3350.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/766,493 US5192802A (en) | 1991-09-25 | 1991-09-25 | Bioadhesive pharmaceutical carrier |
US766,493 | 1991-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2078899A1 true CA2078899A1 (en) | 1993-03-26 |
Family
ID=25076599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002078899A Abandoned CA2078899A1 (en) | 1991-09-25 | 1992-09-23 | Bioadhesive pharmaceutical carrier |
Country Status (2)
Country | Link |
---|---|
US (3) | US5192802A (en) |
CA (1) | CA2078899A1 (en) |
Families Citing this family (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9101986D0 (en) * | 1991-01-30 | 1991-03-13 | Smith & Nephew | Pharmaceutical compositions |
US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
US7060287B1 (en) * | 1992-02-11 | 2006-06-13 | Bioform Inc. | Tissue augmentation material and method |
US6537574B1 (en) | 1992-02-11 | 2003-03-25 | Bioform, Inc. | Soft tissue augmentation material |
US7968110B2 (en) * | 1992-02-11 | 2011-06-28 | Merz Aesthetics, Inc. | Tissue augmentation material and method |
GB9212305D0 (en) * | 1992-06-10 | 1992-07-22 | Applied Research Systems | Sensor for optical assay |
US5670169A (en) * | 1993-12-20 | 1997-09-23 | E.R. Squibb & Sons, Inc. | Wound hydrating gel with novel preservative system and low cytotoxicity |
US5534552A (en) * | 1994-03-02 | 1996-07-09 | Warner-Lambert Company | Clear non-alcoholic sinus and allergy medication |
US5547657A (en) * | 1994-10-11 | 1996-08-20 | Eastman Chemical Company | Low-irritation anesthetic and antiseptic mouth rinse |
US5563153A (en) * | 1995-02-22 | 1996-10-08 | University Of Kansas Medical Center | Sterile topical anesthetic gel |
US5534562A (en) * | 1995-04-07 | 1996-07-09 | Ultradent Products, Inc. | Compositions and methods for priming and sealing dental and biological substrates |
AU2068797A (en) * | 1996-01-29 | 1997-08-20 | Edward Mendell Co. Inc. | Sustained release excipient |
US5912007A (en) * | 1996-02-29 | 1999-06-15 | Warner-Lambert Company | Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same |
IL118235A0 (en) * | 1996-05-13 | 1996-09-12 | Univ Ben Gurion | Composition and method for forming biodegradable implants in situ and uses of these implants |
SE9602226D0 (en) * | 1996-06-05 | 1996-06-05 | Astra Ab | Biocompatible glue |
FR2750859B1 (en) * | 1996-07-12 | 1999-01-22 | Maurel Sante | PHARMACEUTICAL COMPOSITION INTENDED FOR ORAL ADMINISTRATION WITH ABSORPTION OF AT LEAST ONE ACTIVE INGREDIENT THROUGH THE MUCOSA OF THE MOUTH |
SE9603667D0 (en) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
US5955097A (en) * | 1996-10-18 | 1999-09-21 | Virotex Corporation | Pharmaceutical preparation applicable to mucosal surfaces and body tissues |
US5800832A (en) * | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
DE19646392A1 (en) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery |
US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
US20070185032A1 (en) * | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
US6656508B2 (en) * | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
US6319507B1 (en) | 1997-05-02 | 2001-11-20 | Kobo Products, Inc. | Agar gel bead composition and method |
US5961990A (en) * | 1997-05-02 | 1999-10-05 | Kobo Products S.A.R.L. | Cosmetic particulate gel delivery system and method of preparing complex gel particles |
US20020018754A1 (en) * | 1999-03-15 | 2002-02-14 | Paul Albert Sagel | Shapes for tooth whitening strips |
US6096328A (en) * | 1997-06-06 | 2000-08-01 | The Procter & Gamble Company | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
US6416779B1 (en) | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US6572874B1 (en) | 1998-05-15 | 2003-06-03 | Umd, Inc. | Vaginal delivery of bisphosphonates |
US7192984B2 (en) * | 1997-06-17 | 2007-03-20 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use as dermal fillers |
US6869938B1 (en) | 1997-06-17 | 2005-03-22 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use in reducing adhesions |
US20050074495A1 (en) * | 1997-06-17 | 2005-04-07 | Fziomed, Inc. | Compositions of polyacids and methods for their use in reducing adhesions |
US20040096422A1 (en) * | 1997-06-17 | 2004-05-20 | Schwartz Herbert E. | Compositions of polyacids and polyethers and methods for their use in reducing pain |
US20050048102A1 (en) * | 1997-10-16 | 2005-03-03 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
US6174524B1 (en) | 1999-03-26 | 2001-01-16 | Alcon Laboratories, Inc. | Gelling ophthalmic compositions containing xanthan gum |
US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
US6103266A (en) * | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
US7022683B1 (en) | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
US6368625B1 (en) | 1998-08-12 | 2002-04-09 | Cima Labs Inc. | Orally disintegrable tablet forming a viscous slurry |
US20050147690A1 (en) * | 1998-09-25 | 2005-07-07 | Masters David B. | Biocompatible protein particles, particle devices and methods thereof |
US7662409B2 (en) * | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
DE69941498D1 (en) * | 1998-11-12 | 2009-11-12 | Internat Mfg Group Inc | Hemostatic cross-linked dextran beads useful for rapid blood clotting and hemostasis |
US6238711B1 (en) | 1998-11-25 | 2001-05-29 | Wm. Wrigley Jr. Company | Chewing gum with increased flavor release using an aliginate material and method of making |
US6093417A (en) * | 1999-01-11 | 2000-07-25 | Advanced Medical Instruments | Composition to treat ear disorders |
CA2366880C (en) * | 1999-04-02 | 2013-02-12 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use in reducing adhesions |
US6231957B1 (en) | 1999-05-06 | 2001-05-15 | Horst G. Zerbe | Rapidly disintegrating flavor wafer for flavor enrichment |
US6187294B1 (en) * | 1999-06-10 | 2001-02-13 | Russell Anthony Penner | Topical anesthetic prophylaxis composition and the method for use thereof in scaling and polishing teeth |
US20040115252A1 (en) * | 1999-06-25 | 2004-06-17 | Thomas Leon | Methods of treating illnesses in non-human mammals |
US20020076440A1 (en) * | 1999-06-25 | 2002-06-20 | Thomas Leon | Veterinary delivery systems and methods of delivering effective agents to animals |
KR20020032521A (en) | 1999-07-02 | 2002-05-03 | 데이비드 엠 모이어 | Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip |
ATE243038T1 (en) | 1999-11-01 | 2003-07-15 | Alcon Inc | PHARMACEUTICAL COMPOSITIONS CONTAINING A FLUOROCHINOLONE ANTIBIOTIC AND XANTHANG GUM |
US6432415B1 (en) | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
US6566345B2 (en) | 2000-04-28 | 2003-05-20 | Fziomed, Inc. | Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
IT1315274B1 (en) * | 1999-12-29 | 2003-02-03 | Cip Ninety Two 92 Sa | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION LOCALIZED IN THE ORAL CABLE OF NON STEREOID ANTI-INFLAMMATORY DRUGS USEFUL FOR |
US6841544B2 (en) * | 2000-02-23 | 2005-01-11 | Bioselect Innovations, Inc. | Composition and method for treating the effects of diseases and maladies |
US6787164B2 (en) * | 2000-02-23 | 2004-09-07 | Bioselect Innovations, Inc. | Composition and method for treating the effects of diseases and maladies |
AU2001259177A1 (en) * | 2000-04-28 | 2001-11-12 | Fziomed, Inc. | Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
IL137559A (en) * | 2000-07-27 | 2006-12-31 | Amnon Sintov | Transdermal drug delivery system |
MXPA03000813A (en) | 2000-07-28 | 2005-08-16 | Alcon Inc | Pharmaceutical compositions containing tobramycin and xanthan gum. |
US7803392B2 (en) * | 2000-12-27 | 2010-09-28 | University Of Kentucky Research Foundation | pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules |
US6468557B1 (en) * | 2001-01-05 | 2002-10-22 | Alphamed Pharmaceutical Corp. | Method for treating infectious viral diseases |
US10004684B2 (en) * | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
US6730330B2 (en) | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
GB2380129B (en) * | 2001-02-14 | 2004-08-11 | Gw Pharma Ltd | Pharmaceutical formulations |
US7544348B2 (en) * | 2001-02-15 | 2009-06-09 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
DK1363600T3 (en) * | 2001-02-15 | 2009-01-26 | Access Pharma Inc | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
US7494669B2 (en) * | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
US6777000B2 (en) * | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
US6660292B2 (en) | 2001-06-19 | 2003-12-09 | Hf Flavoring Technology Llp | Rapidly disintegrating flavored film for precooked foods |
US20060073174A1 (en) * | 2001-08-16 | 2006-04-06 | Access Pharmaceuticals, Inc. | Adherent and erodible film to treat a moist surface of a body tissue |
US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
US20030083286A1 (en) * | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
US20030124196A1 (en) * | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
US6899700B2 (en) | 2001-08-29 | 2005-05-31 | Kimberly-Clark Worldwide, Inc. | Therapeutic agent delivery tampon |
US7910641B2 (en) | 2001-10-12 | 2011-03-22 | Monosol Rx, Llc | PH modulated films for delivery of actives |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US7666337B2 (en) * | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
US8663687B2 (en) | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US7357891B2 (en) * | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
US20050064027A1 (en) * | 2001-12-15 | 2005-03-24 | Spherics, Inc. | Bioadhesive drug delivery system with enhanced gastric retention |
US6888043B2 (en) | 2001-12-21 | 2005-05-03 | Kimberly-Clark Worldwide, Inc. | Feminine care products for the delivery of therapeutic substances |
US20030120225A1 (en) * | 2001-12-21 | 2003-06-26 | Kimberly-Clark Worldwide, Inc. | Therapeutic agent delivery labial pad |
US6729879B2 (en) | 2002-03-13 | 2004-05-04 | Ultradent Products, Inc. | Dental bonding methods for adhering amalgam restoratives to dental substrates |
US6756417B2 (en) * | 2002-03-13 | 2004-06-29 | Ultradent Products, Inc. | Dental bonding compositions for adhering amalgam restoratives to dental substrates |
US8017150B2 (en) | 2002-04-11 | 2011-09-13 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
WO2003092468A2 (en) * | 2002-04-29 | 2003-11-13 | Gel-Del Technologies, Inc. | Biomatrix structural containment and fixation systems and methods of use thereof |
US6919348B2 (en) * | 2002-05-02 | 2005-07-19 | Edward T. Wei | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith |
US6949240B2 (en) * | 2002-05-23 | 2005-09-27 | The Procter & Gamble Company | Tooth whitening products |
AU2003241134A1 (en) * | 2002-06-20 | 2004-01-06 | Amnon Sintov | Transdermal drug delivery system |
US8524200B2 (en) | 2002-09-11 | 2013-09-03 | The Procter & Gamble Company | Tooth whitening products |
US20050019277A1 (en) * | 2002-09-11 | 2005-01-27 | The Procter & Gamble Company | Tooth whitening products |
EA012306B1 (en) * | 2003-01-24 | 2009-08-28 | Магле Холдинг Аб | A composition material for transmucosal delivery |
SE0302947D0 (en) * | 2003-01-24 | 2003-11-07 | Magle Ab | A composition material for transmucosal delivery |
SE0300187D0 (en) * | 2003-01-24 | 2003-01-24 | Magle Ab | A smokeless tobacco substitute material |
GB2398496A (en) * | 2003-02-20 | 2004-08-25 | Reckitt Benckiser Healthcare | Suspensions of water-swellable polymer particles which are substantially water-free or contain insufficient water to fully swell the particles |
CA2517828C (en) * | 2003-03-21 | 2016-10-04 | Nexmed Holdings, Inc. | Compositions and methods for treatment of premature ejaculation |
US20060193825A1 (en) * | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
US20050112087A1 (en) * | 2003-04-29 | 2005-05-26 | Musso Gary F. | Pharmaceutical formulations for sustained drug delivery |
US8465537B2 (en) * | 2003-06-17 | 2013-06-18 | Gel-Del Technologies, Inc. | Encapsulated or coated stent systems |
AU2003265624B2 (en) * | 2003-08-21 | 2011-03-31 | Abeona Therapeutics Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
CA2537315C (en) | 2003-08-26 | 2015-12-08 | Gel-Del Technologies, Inc. | Protein biomaterials and biocoacervates and methods of making and using thereof |
US20050058673A1 (en) | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
CA2548822C (en) * | 2003-12-08 | 2015-08-11 | Gel-Del Technologies, Inc. | Mucoadhesive drug delivery devices and methods of making and using thereof |
EP1708668A1 (en) * | 2004-01-15 | 2006-10-11 | Oral Bioscience Pty. Limited | Oral anaesthetic gel |
WO2006026504A2 (en) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Mucoadhesive oral formulations of high permeability, high solubility drugs |
US20060045865A1 (en) * | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
US9028852B2 (en) | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
US8198326B2 (en) * | 2004-09-07 | 2012-06-12 | 3M Innovative Properties Company | Phenolic antiseptic compositions and methods of use |
US20060051384A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Antiseptic compositions and methods of use |
CZ296169B6 (en) * | 2004-09-08 | 2006-01-11 | Pliva - Lachema A. S. | Pharmaceutical composition for rectal or vaginal administration, process for its preparation and its use as medicament |
US20080274206A1 (en) * | 2004-10-07 | 2008-11-06 | Ngen Pharmaceuticals N.V. | Stabilised Oxygen Releasing Composition |
CN101072592B (en) * | 2004-10-07 | 2012-03-14 | 恩根医药有限公司 | Application of liquid composition for treating wounds and burns in the drugs |
DE102005059420B4 (en) * | 2004-12-09 | 2008-11-20 | Axel Hensel | Use of a hypromellose-containing adhesive paste pressed into a buccal tablet for the treatment of local diseases of the oral mucosa |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
WO2006086750A1 (en) * | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Liquid formulations for treatment of diseases or conditions |
US8476319B2 (en) * | 2005-03-10 | 2013-07-02 | 3M Innovative Properties Company | Methods of treating ear infections |
EP1898900B1 (en) * | 2005-03-10 | 2011-06-08 | 3M Innovative Properties Company | Antimicrobial compositions comprising esters of hydroxycarboxylic acids |
US10918618B2 (en) * | 2005-03-10 | 2021-02-16 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
WO2006102378A2 (en) * | 2005-03-21 | 2006-09-28 | Macusight, Inc. | Drug delivery systems for treatment of diseases or conditions |
WO2006122183A2 (en) * | 2005-05-10 | 2006-11-16 | Cytophil, Inc. | Injectable hydrogels and methods of making and using same |
US8263047B2 (en) * | 2005-09-29 | 2012-09-11 | Wickenhauser Alan J | Topical anesthetic for dental procedures |
US8623334B1 (en) | 2005-09-29 | 2014-01-07 | Alan J. Wickenhauser | Topical anesthetic |
SE530184C2 (en) * | 2005-12-23 | 2008-03-18 | Kjell Stenberg | Bioadhesive pharmaceutical film composition containing low viscous alginates |
US20070184087A1 (en) * | 2006-02-06 | 2007-08-09 | Bioform Medical, Inc. | Polysaccharide compositions for use in tissue augmentation |
JP5528708B2 (en) | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | Stable formulations and methods for preparing and using them |
US8222271B2 (en) | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
US20070248653A1 (en) * | 2006-04-20 | 2007-10-25 | Cochrum Kent C | Hemostatic compositions and methods for controlling bleeding |
BRPI0714712B8 (en) | 2006-07-21 | 2021-05-25 | Biodelivery Sciences Int Inc | drug delivery device |
CN101138541B (en) * | 2006-09-06 | 2010-10-06 | 上海医药工业研究院 | Amlexanox partial film forming gel composition and uses thereof |
JP4739452B2 (en) | 2006-09-20 | 2011-08-03 | モノソル アールエックス リミテッド ライアビリティ カンパニー | Eatable water-soluble film containing flavor enhancer to reduce foaming |
EP2091324B1 (en) | 2006-10-27 | 2016-12-28 | 3M Innovative Properties Company | Antimicrobial compositions |
WO2009026349A1 (en) * | 2007-08-21 | 2009-02-26 | Archer-Daniels-Midland Company | Hydrocolloid gum compositions, methods of forming the same, and products formed therefrom |
AU2008345047A1 (en) * | 2007-12-26 | 2009-07-09 | Gel-Del Technologies, Inc. | Biocompatible protein particles, particle devices and methods thereof |
US9265779B2 (en) | 2008-05-13 | 2016-02-23 | Lts Lohmann Therapie-Systeme Ag | Method of using a film-shaped preparation comprising oily substances for oral administration |
DE102008023345B4 (en) * | 2008-05-13 | 2014-12-04 | Lts Lohmann Therapie-Systeme Ag | Film-like preparation with oily substances for oral administration |
WO2010057177A2 (en) | 2008-11-17 | 2010-05-20 | Gel-Del Technologies, Inc. | Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof |
JP5724108B2 (en) * | 2009-04-22 | 2015-05-27 | メドスキン ソリューションズ ドクター ズベラック アーゲーMedSkin Solutions Dr.Suwelack AG | Lyophilized composition |
US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
US8701671B2 (en) | 2011-02-04 | 2014-04-22 | Joseph E. Kovarik | Non-surgical method and system for reducing snoring |
US9549842B2 (en) | 2011-02-04 | 2017-01-24 | Joseph E. Kovarik | Buccal bioadhesive strip and method of treating snoring and sleep apnea |
EP2504019A2 (en) | 2009-11-25 | 2012-10-03 | ArisGen SA | Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion |
US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
US20110136815A1 (en) | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
US10039709B2 (en) * | 2010-06-04 | 2018-08-07 | Trilogic Pharma Llc | Bioadhesive compositions for epithelial drug delivery |
EP2579844B1 (en) | 2010-06-10 | 2016-02-24 | Midatech Ltd. | Nanoparticle film delivery systems |
US20120004303A1 (en) * | 2010-06-30 | 2012-01-05 | Church & Dwight Co., Inc. | Method of dispensing a teething gel with a metered dose applicator |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
BR112014003651B1 (en) | 2011-08-18 | 2022-03-29 | Biodelivery Sciences International, Inc | Misuse-resistant mucoadhesive devices for the release of buprenorphine |
SI2915525T1 (en) | 2011-09-19 | 2022-01-31 | Orexo Ab | Sublingual abuse-resistant tablets comprising buprenorphine and naloxone |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
JOP20200109A1 (en) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | Injectable preparation |
US9173941B1 (en) | 2012-08-02 | 2015-11-03 | Jeff Shear | Sustained release bittering composition |
CA2888199C (en) | 2012-10-17 | 2019-06-25 | The Procter & Gamble Company | Strip for the delivery of an oral care active and methods for applying oral care actives |
WO2014071203A1 (en) * | 2012-11-02 | 2014-05-08 | University Of Kentucky Research Foundation | Sustained release of topical anesthetics |
KR20150142691A (en) * | 2013-03-15 | 2015-12-22 | 씨비에이 파마, 인크. | Tetrandrine family pharmaceutical formulations and method |
WO2014186742A2 (en) * | 2013-05-17 | 2014-11-20 | Acupac Packaging, Inc. | Anhydrous hydrogel composition |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
EP2889030A1 (en) | 2013-12-30 | 2015-07-01 | Uluru Inc. | Controlling the erosion rates of mucoadhesive devices that deliver actives and other compounds and providing increased and variable therapeutic blood levels |
US10799724B2 (en) | 2015-10-22 | 2020-10-13 | Colgate-Palmolive Company | Oral care compositions |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
WO2017192921A1 (en) | 2016-05-05 | 2017-11-09 | Monosol Rx, Llc | Enhanced delivery epinephrine compositions |
IE87094B1 (en) | 2017-08-04 | 2020-05-13 | Laboratorios Kin S A | Gel comprising chlorhexidine |
GB2575625A (en) * | 2018-06-22 | 2020-01-22 | Church & Dwight Co Inc | Oral care compositions comprising benzocaine and mucoadhesive thin films formed therefrom |
US11185526B2 (en) | 2018-09-04 | 2021-11-30 | Babak Ghalili | Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods |
US10695301B2 (en) | 2018-09-04 | 2020-06-30 | Babak Ghalili | Veterinary cannabinoid and menthol compositions and methods |
US10966924B2 (en) | 2018-09-04 | 2021-04-06 | Babak Ghalili | Veterinary cannabinoid, menthol and anesthetic compositions and methods |
US20200069604A1 (en) * | 2018-09-04 | 2020-03-05 | Babak Ghalili | Cannabinoid and anesthetic compositions and methods |
US11147775B2 (en) | 2018-09-04 | 2021-10-19 | Babak Ghalili | Cannabinoid and menthol gel compositions, patches and methods |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL287272A (en) * | 1962-04-26 | |||
JPS5562012A (en) * | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
US4241048A (en) * | 1979-05-01 | 1980-12-23 | Bristol-Myers Company | Suspension composition of benzocaine |
JPS57142913A (en) * | 1981-02-27 | 1982-09-03 | Nitto Electric Ind Co Ltd | Donor of physiologically active substance |
US4518721A (en) * | 1982-03-26 | 1985-05-21 | Richardson-Vicks Inc. | Hydrophilic denture adhesive |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
JPS6011631A (en) * | 1983-07-01 | 1985-01-21 | Toyota Motor Corp | Turbine housing for turbocharger |
US5057306A (en) * | 1983-11-06 | 1991-10-15 | Hill Ira D | Method of manufacturing oral hygiene gels |
GB2181957A (en) * | 1985-10-29 | 1987-05-07 | Kenneth Needham | Teething dummy |
US5009881A (en) * | 1986-11-06 | 1991-04-23 | Hill Ira D | Oral hygiene gels |
US5057307A (en) * | 1986-11-06 | 1991-10-15 | Hill Ira D | Method of relieving gum discomfort |
DE3704907A1 (en) * | 1987-02-17 | 1988-08-25 | Bayer Ag | TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS |
DE3714074A1 (en) * | 1987-04-28 | 1988-11-10 | Hoechst Ag | BASIS FOR MUCUTINE AND PROSTHESISAL PASTE, METHOD FOR THEIR PRODUCTION AND PASTE BASED ON THIS BASE |
US4867970A (en) * | 1987-05-21 | 1989-09-19 | E. R. Squibb & Sons, Inc. | Moistureless oral drug delivery formulation and method for preparing same |
DE3726797A1 (en) * | 1987-08-12 | 1989-02-23 | Bayer Ag | MEDICINAL PRODUCTS FOR ORAL CAVES |
US4915948A (en) * | 1987-08-31 | 1990-04-10 | Warner-Lambert Company | Tablets having improved bioadhesion to mucous membranes |
US5059189A (en) * | 1987-09-08 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Method of preparing adhesive dressings containing a pharmaceutically active ingredient |
US5002974A (en) * | 1988-04-04 | 1991-03-26 | Warner-Lambert Co. | Anesthetic/skin moisturizing composition and method of preparing same |
JPH01259356A (en) * | 1988-04-11 | 1989-10-17 | Agency Of Ind Science & Technol | Optical recording medium |
WO1989010117A1 (en) * | 1988-04-19 | 1989-11-02 | Southwest Research Institute | Controlled release of active ingredients from capsules having a salt sensitive shell material |
JPH01279838A (en) * | 1988-04-30 | 1989-11-10 | Kiyuukiyuu Yakuhin Kogyo Kk | Lysozyme chloride-containing plaster for gingivitis and pyorrhea |
US4981815A (en) * | 1988-05-09 | 1991-01-01 | Siemens Aktiengesellschaft | Method for rapidly thermally processing a semiconductor wafer by irradiation using semicircular or parabolic reflectors |
US4999342A (en) * | 1988-08-16 | 1991-03-12 | Ortho Pharmaceutical Corporation | Long lasting contraceptive suppository composition and methods of use |
LU87410A1 (en) * | 1988-12-20 | 1990-07-10 | Cird | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING POLYMERIC OR FATTY BODY MICROSPHERES CHARGED WITH AT LEAST ONE ACTIVE PRODUCT |
US4989607A (en) * | 1989-03-30 | 1991-02-05 | Preston Keusch | Highly conductive non-stringy adhesive hydrophilic gels and medical electrode assemblies manufactured therefrom |
US5102870A (en) * | 1989-04-14 | 1992-04-07 | Schering Ag | Treatment and prevention of oral mucositis with growth factors |
US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
-
1991
- 1991-09-25 US US07/766,493 patent/US5192802A/en not_active Expired - Lifetime
-
1992
- 1992-09-23 CA CA002078899A patent/CA2078899A1/en not_active Abandoned
- 1992-12-16 US US07/991,696 patent/US5314915A/en not_active Expired - Lifetime
-
1994
- 1994-04-26 US US08/220,314 patent/US5462749A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5462749A (en) | 1995-10-31 |
US5192802A (en) | 1993-03-09 |
US5314915A (en) | 1994-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5192802A (en) | Bioadhesive pharmaceutical carrier | |
US6610667B1 (en) | Compositions for treatment of disorders of the oesophagus | |
EP1997478B1 (en) | Liquid formulations for the prevention and treatment of mucosal diseases and disorders | |
US4680323A (en) | Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration | |
JP4336021B2 (en) | Orally disintegrating tablet and method for producing the same | |
US6828308B2 (en) | Compositions and methods for the treatment or prevention of inflammation | |
US8569375B2 (en) | Compositions | |
CN1207677A (en) | Pharmaceutical compositions comprising flurbiprofen | |
US20020173485A1 (en) | Compositions and methods for the treatment or prevention of inflammation | |
JPH02300114A (en) | Remedy transmitting composite and trauma bandage composite | |
PT1965787E (en) | Treatment of xerostomia with a sulfur-containing antioxidant | |
JPH08253412A (en) | Gelling agent for polyethylene glycol | |
US20070134280A1 (en) | Thixotropic ingestible formulation to treat sore throat | |
WO2001030391A2 (en) | Pharmaceutical composition containing midazolam | |
Darade et al. | Oral medicated jellies as a emerging platform for oral drug delivery in pediatrics | |
CA2366411A1 (en) | Topical medicated bioadhesive compositions and methods of use and preparation thereof | |
NZ198858A (en) | Pharmaceutical composition containing sodium cromoglycate | |
JP2008133294A (en) | Tablet disintegrated in buccal cavity | |
Russell et al. | Oropharynx | |
Dreijer-van der Glas | Oropharynx | |
MXPA01011235A (en) | Compositions for treatment of disorders of the oesophagus | |
AU2002251967A1 (en) | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |